Human systems immunology: Hypothesis-based modeling and unbiased data-driven approaches

Seminars in Immunology

Volumn 25, Issue 3, 2013, Pages 193-200

  Arazi, Arnon ^b   Pendergraft, William F ^a,b,c   Ribeiro, Ruy M ^d,e   Perelson, Alan S ^d   Hacohen, Nir ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d LOS ALAMOS NATIONAL LABORATORY   (United States)

^e INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Autoimmunity; Dynamical modeling; Hypothesis based modeling; Systems immunology; Unbiased data driven approaches; Viral infections

Indexed keywords

ANTIRETROVIRUS AGENT; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 6;

ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DATA DRIVEN MODELING; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; GENE EXPRESSION; HEPATITIS B; HEPATITIS C; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHESIS BASED MODELING; IMMUNE RESPONSE; IMMUNOLOGY; INFLUENZA A; PATHOGENESIS; PROCESS MODEL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMS BIOLOGY; SYSTEMS IMMUNOLOGY; T CELL DEPLETION; TREATMENT OUTCOME; TURNOVER TIME; VIRUS CELL INTERACTION; VIRUS CONCENTRATION;

AUTOIMMUNITY; DYNAMICAL MODELING; HYPOTHESIS-BASED MODELING; SYSTEMS IMMUNOLOGY; UNBIASED DATA-DRIVEN APPROACHES; VIRAL INFECTIONS;

ALLERGY AND IMMUNOLOGY; AUTOIMMUNE DISEASES; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNE SYSTEM; MODELS, BIOLOGICAL; SYSTEMS BIOLOGY; VIRUS DISEASES;

EID: 84887606996     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2012.11.003     Document Type: Review

References (115)

1. Kirschner M.W. The meaning of systems biology. Cell 2005, 121:503-504.
2. Benoist C., Germain R.N., Mathis D. A plaidoyer for 'systems immunology'. Immunological Reviews 2006, 210:229-234.
3. Zak D.E., Aderem A. Systems biology of innate immunity. Immunological Reviews 2009, 227:264-282.
4. Germain R.N., Meier-Schellersheim M., Nita-Lazar A., Fraser I.D. Systems biology in immunology: a computational modeling perspective. Annual Review of Immunology 2011, 29:527-585.
5. Amit I., Regev A., Hacohen N. Strategies to discover regulatory circuits of the mammalian immune system. Nature Reviews Immunology 2011, 11:873-880.
6. Chuang H.Y., Hofree M., Ideker T. A decade of systems biology. Annual Review of Cell and Developmental Biology 2010, 26:721-744.
7. Kholodenko B., Yaffe M.B., Kolch W. Computational approaches for analyzing information flow in biological networks. Science Signaling 2012, 5:re1.
8. Chaussabel D., Pascual V., Banchereau J. Assessing the human immune system through blood transcriptomics. BMC Biology 2010, 8:84.
9. Roedder S., Vitalone M., Khatri P., Sarwal M.M. Biomarkers in solid organ transplantation: establishing personalized transplantation medicine. Genome Medicine 2011, 3:37.
10. Nakaya H.I., Wrammert J., Lee E.K., Racioppi L., Marie-Kunze S., Haining W.N., et al. Systems biology of vaccination for seasonal influenza in humans. Nature Immunology 2011, 12:786-795.
11. Nakaya H.I., Li S., Pulendran B. Systems vaccinology: learning to compute the behavior of vaccine induced immunity. Wiley Interdisciplinary Review Systems Biology and Medicine 2012, 4:193-205.
12. Perelson A.S., Weisbuch G. Immunology for physicists. Review of Modern Physics 1997, 69:1219-1268.
13. Perelson A.S. Modelling viral and immune system dynamics. Nature Reviews Immunology 2002, 2:28-36.
14. Antia R., Ganusov V.V., Ahmed R. The role of models in understanding CD8+ T-cell memory. Nature Reviews Immunology 2005, 5:101-111.
15. Wei X., Ghosh S.K., Taylor M.E., Johnson V.A., Emini E.A., Deutsch P., et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
16. Ho D.D., Neumann A.U., Perelson A.S., Chen W., Leonard J.M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
17. Markowitz M., Louie M., Hurley A., Sun E., Di Mascio M., Perelson A.S., et al. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. Journal of Virology 2003, 77:5037-5038.
18. Ganusov V.V., Goonetilleke N., Liu M.K., Ferrari G., Shaw G.M., McMichael A.J., et al. Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection. Journal of Virology 2011, 85:10518-10528.
19. Tomaras G.D., Yates N.L., Liu P., Qin L., Fouda G.G., Chavez L.L., et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. Journal of Virology 2008, 82:12449-12463.
20. Layden T.J., Layden J.E., Ribeiro R.M., Perelson A.S. Mathematical modeling of viral kinetics: a tool to understand and optimize therapy. Clinics in Liver Disease 2003, 7:163-178.
21. Hellerstein M., Hanley M.B., Cesar D., Siler S., Papageorgopoulos C., Wieder E., et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nature Medicine 1999, 5:83-89.
22. Mohri H., Perelson A.S., Tung K., Ribeiro R.M., Ramratnam B., Markowitz M., et al. Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. Journal of Experimental Medicine 2001, 194:1277-1287.
23. Ribeiro R.M., Mohri H., Ho D.D., Perelson A.S. In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: why are CD4+ but not CD8+ T cells depleted?. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:15572-15577.
24. Asquith B., Debacq C., Macallan D.C., Willems L., Bangham C.R. Lymphocyte kinetics: the interpretation of labelling data. Trends in Immunology 2002, 23:596-601.
25. Hellerstein M.K., Hoh R.A., Hanley M.B., Cesar D., Lee D., Neese R.A., et al. Subpopulations of long-lived and short-lived T cells in advanced HIV-1 infection. Journal of Clinical Investigation 2003, 112:956-966.
26. Vrisekoop N., den Braber I., de Boer A.B., Ruiter A.F., Ackermans M.T., van der Crabben S.N., et al. Sparse production but preferential incorporation of recently produced naive T cells in the human peripheral pool. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:6115-6120.
27. Ganusov V.V., Borghans J.A., De Boer R.J. Explicit kinetic heterogeneity: mathematical models for interpretation of deuterium labeling of heterogeneous cell populations. PLOS Computational Biology 2010, 6:e1000666.
28. De Boer R.J., Perelson A.S., Ribeiro R.M. Modelling deuterium labelling of lymphocytes with temporal and/or kinetic heterogeneity. Journal of the Royal Society Interface 2012, 9:2191-2200.
29. Douek D.C., McFarland R.D., Keiser P.H., Gage E.A., Massey J.M., Haynes B.F., et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998, 396:690-695.
30. Hazenberg M.D., Otto S.A., Cohen Stuart J.W., Verschuren M.C., Borleffs J.C., Boucher C.A., et al. Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nature Medicine 2000, 6:1036-1042.
31. Lewin S.R., Ribeiro R.M., Kaufmann G.R., Smith D., Zaunders J., Law M., et al. Dynamics of T cells and TCR excision circles differ after treatment of acute and chronic HIV infection. Journal of Immunology 2002, 169:4657-4666.
32. Arron S.T., Ribeiro R.M., Gettie A., Bohm R., Blanchard J., Yu J., et al. Impact of thymectomy on the peripheral T cell pool in rhesus macaques before and after infection with simian immunodeficiency virus. European Journal of Immunology 2005, 35:46-55.
33. Kong F., Chen C.H., Cooper M.D. Thymic function can be accurately monitored by the level of recent T cell emigrants in the circulation. Immunity 1998, 8:97-104.
34. Perelson A.S., Neumann A.U., Markowitz M., Leonard J.M., Ho D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586.
35. Ramratnam B., Bonhoeffer S., Binley J., Hurley A., Zhang L., Mittler J.E., et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 1999, 354:1782-1785.
36. Coffin J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267:483-489.
37. Perelson A.S., Essunger P., Ho D.D. Dynamics of HIV-1 and CD4+ lymphocytes in vivo. AIDS 1997, 11(Suppl. A):S17-S24.
38. Perelson A.S., Essunger P., Cao Y., Vesanen M., Hurley A., Saksela K., et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387:188-191.
39. Hlavacek W.S., Stilianakis N.I., Notermans D.W., Danner S.A., Perelson A.S. Influence of follicular dendritic cells on decay of HIV during antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:10966-10971.
40. Kepler T.B., Perelson A.S. Drug concentration heterogeneity facilitates the evolution of drug resistance. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:11514-11519.
41. Callaway D.S., Perelson A.S. HIV-1 infection and low steady state viral loads. Bulletin of Mathematical Biology 2002, 64:29-64.
42. Rong L., Perelson A.S. Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLOS Computational Biology 2009, 5:e1000533.
43. Rong L., Perelson A.S. Modeling HIV persistence, the latent reservoir, and viral blips. Journal of Theoretical Biology 2009, 260:308-331.
44. Finzi D., Blankson J., Siliciano J.D., Margolick J.B., Chadwick K., Pierson T., et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Medicine 1999, 5:512-517.
45. Ramratnam B., Mittler J.E., Zhang L., Boden D., Hurley A., Fang F., et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nature Medicine 2000, 6:82-85.
46. Kim H., Perelson A.S. Viral and latent reservoir persistence in HIV-1-infected patients on therapy. PLOS Computational Biology 2006, 2:e135.
47. Rong L., Perelson A.S. Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips. Mathematical Biosciences 2009, 217:77-87.
48. Chomont N., El-Far M., Ancuta P., Trautmann L., Procopio F.A., Yassine-Diab B., et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nature Medicine 2009, 15:893-900.
49. Ribeiro R.M., Lo A., Perelson A.S. Dynamics of hepatitis B virus infection. Microbes and Infection 2002, 4:829-835.
50. Baccam P., Beauchemin C., Macken C.A., Hayden F.G., Perelson A.S. Kinetics of influenza A virus infection in humans. Journal of Virology 2006, 80:7590-7599.
51. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Layden T.J., et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282:103-107.
52. Chung R.T., He W., Saquib A., Contreras A.M., Xavier R.J., Chawla A., et al. Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:9847-9852.
53. Castet V., Fournier C., Soulier A., Brillet R., Coste J., Larrey D., et al. Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. Journal of Virology 2002, 76:8189-8199.
54. Feld J.J., Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005, 436:967-972.
55. Crotty S., Cameron C.E., Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:6895-6900.
56. Dixit N.M., Layden-Almer J.E., Layden T.J., Perelson A.S. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004, 432:922-924.
57. Shapira S.D., Hacohen N. Systems biology approaches to dissect mammalian innate immunity. Current Opinion in Immunology 2011, 23:71-77.
58. Ramilo O., Allman W., Chung W., Mejias A., Ardura M., Glaser C., et al. Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood 2007, 109:2066-2077.
59. Ura S., Honda M., Yamashita T., Ueda T., Takatori H., Nishino R., et al. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 2009, 49:1098-1112.
60. Yang J., Zhao X., Liu X., Wang C., Gao P., Wang J., et al. High performance liquid chromatography-mass spectrometry for metabonomics: potential biomarkers for acute deterioration of liver function in chronic hepatitis B. Journal of Proteome Research 2006, 5:554-561.
61. White I.R., Patel K., Symonds W.T., Dev A., Griffin P., Tsokanas N., et al. Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection. Journal of Translational Medicine 2007, 5:33.
62. Cheung K.J., Tilleman K., Deforce D., Colle I., Van Vlierberghe H. The HCV serum proteome: a search for fibrosis protein markers. Journal of Viral Hepatitis 2009, 16:418-429.
63. Diamond D.L., Jacobs J.M., Paeper B., Proll S.C., Gritsenko M.A., Carithers R.L., et al. Proteomic profiling of human liver biopsies: hepatitis C virus-induced fibrosis and mitochondrial dysfunction. Hepatology 2007, 46:649-657.
64. Chun T.W., Justement J.S., Lempicki R.A., Yang J., Dennis G., Hallahan C.W., et al. Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:1908-1913.
65. Houzet L., Yeung M.L., de Lame V., Desai D., Smith S.M., Jeang K.T. MicroRNA profile changes in human immunodeficiency virus type 1 (HIV-1) seropositive individuals. Retrovirology 2008, 5:118.
66. Bigger C.B., Brasky K.M., Lanford R.E. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. Journal of Virology 2001, 75:7059-7066.
67. Kobasa D., Jones S.M., Shinya K., Kash J.C., Copps J., Ebihara H., et al. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 2007, 445:319-323.
68. Brown J.N., Palermo R.E., Baskin C.R., Gritsenko M., Sabourin P.J., Long J.P., et al. Macaque proteome response to highly pathogenic avian influenza and 1918 reassortant influenza virus infections. Journal of Virology 2010, 84:12058-12068.
69. Zaas A.K., Chen M., Varkey J., Veldman T., Hero A.O., Lucas J., et al. Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host and Microbe 2009, 6:207-217.
70. Huang Y., Zaas A.K., Rao A., Dobigeon N., Woolf P.J., Veldman T., et al. Temporal dynamics of host molecular responses differentiate symptomatic and asymptomatic influenza a infection. PLoS Genetics 2011, 7:e1002234.
71. Guadalupe M., Reay E., Sankaran S., Prindiville T., Flamm J., McNeil A., et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. Journal of Virology 2003, 77:11708-11717.
72. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
73. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O'Huigin C., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
74. Patel K., Lucas J.E., Thompson J.W., Dubois L.G., Tillmann H.L., Thompson A.J., et al. High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients. Hepatology 2011, 53:1809-1818.
75. Bergman R.N., Phillips L.S., Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. Journal of Clinical Investigation 1981, 68:1456-1467.
76. Cobelli C., Caumo A., Omenetto M. Minimal model SG overestimation and SI underestimation: improved accuracy by a Bayesian two-compartment model. American Journal of Physiology 1999, 277:E481-E488.
77. Topp B., Promislow K., deVries G., Miura R.M., Finegood D.T. A model of beta-cell mass, insulin, and glucose kinetics: pathways to diabetes. Journal of Theoretical Biology 2000, 206:605-619.
78. Bonner-Weir S. beta-cell turnover: its assessment and implications. Diabetes 2001, 50(Suppl. 1):S20-S24.
79. Chen M., Bergman R.N., Pacini G., Porte D. Pathogenesis of age-related glucose intolerance in man: insulin resistance and decreased beta-cell function. The Journal of clinical endocrinology and metabolism 1985, 60:13-20.
80. Ward W.K., Johnston C.L., Beard J.C., Benedetti T.J., Halter J.B., Porte D. Insulin resistance and impaired insulin secretion in subjects with histories of gestational diabetes mellitus. Diabetes 1985, 34:861-869.
81. Chang R.J., Geffner M.E. Associated non-ovarian problems of polycystic ovarian disease: insulin resistance. Clinics in Obstetrics and Gynaecology 1985, 12:675-685.
82. Raghu P., Johnston C., Beard J.C., Bergman R., McCulloch D.K., Palmer J.P. Reduced insulin sensitivity in nondiabetic, HLA-identical siblings of insulin-dependent diabetic subjects. Diabetes 1985, 34:991-994.
83. Finegood D.T., Hramiak I.M., Dupre J. A modified protocol for estimation of insulin sensitivity with the minimal model of glucose kinetics in patients with insulin-dependent diabetes. The Journal of clinical endocrinology and metabolism 1990, 70:1538-1549.
84. Rickels M.R., Naji A., Teff K.L. Insulin sensitivity, glucose effectiveness, and free fatty acid dynamics after human islet transplantation for type 1 diabetes. The Journal of clinical endocrinology and metabolism 2006, 91:2138-2144.
85. Kimberly R.P., Meryhew N.L., Runquist O.A. Mononuclear phagocyte function in SLE. I. Bipartite Fc- and complement-dependent dysfunction. Journal of Immunology 1986, 137:91-96.
86. Meryhew N.L., Kimberly R.P., Messner R.P., Runquist O.A. Mononuclear phagocyte system in SLE. II. A kinetic model of immune complex handling in systemic lupus erythematosus. Journal of Immunology 1986, 137:97-102.
87. Mahaffy J.M., Edelstein-Keshet L. Modeling cyclic waves of circulating T cells in autoimmune diabetes. SIAM Journal on Applied Mathematics 2007, 67:915-937.
88. Budu-Grajdeanu P., Schugart R.C., Friedman A., Birmingham D.J., Rovin B.H. Mathematical framework for human SLE Nephritis: disease dynamics and urine biomarkers. Theoretical Biology and Medical Modelling 2010, 7:14.
89. Cohen I.R., Atlan H. Network regulation of autoimmunity: an automation model. Journal of Autoimmunity 1989, 2:613-625.
90. Segel L.A., Jager E. Reverse engineering: a model for T-cell vaccination. Bulletin of Mathematical Biology 1994, 56:687-721.
91. Borghans J.A., De Boer R.J. A minimal model for T-cell vaccination. Proceedings of the Royal Society B: Biological Sciences 1995, 259:173-178.
92. Borghans J.A., De Boer R.J., Sercarz E., Kumar V. T cell vaccination in experimental autoimmune encephalomyelitis: a mathematical model. Journal of Immunology 1998, 161:1087-1093.
93. Segel L.A., Jager E., Elias D., Cohen I.R. A quantitative model of autoimmune disease and T-cell vaccination: does more mean less?. Immunology Today 1995, 16:80-84.
94. Maree A.F., Kublik R., Finegood D.T., Edelstein-Keshet L. Modelling the onset of Type 1 diabetes: can impaired macrophage phagocytosis make the difference between health and disease?. Philosophical Transactions Series A: Mathematical, Physical, and Engineering Sciences 2006, 364:1267-1282.
95. Khadra A., Santamaria P., Edelstein-Keshet L. The role of low avidity T cells in the protection against type 1 diabetes: a modeling investigation. Journal of Theoretical Biology 2009, 256:126-141.
96. Khadra A., Tsai S., Santamaria P., Edelstein-Keshet L. On how monospecific memory-like autoregulatory CD8+ T cells can blunt diabetogenic autoimmunity: a computational approach. Journal of Immunology 2010, 185:5962-5972.
97. Meyer-Hermann M., Figge M.T., Straub R.H. Mathematical modeling of the circadian rhythm of key neuroendocrine-immune system players in rheumatoid arthritis: a systems biology approach. Arthritis and Rheumatism 2009, 60:2585-2594.
98. Maas K., Chen H., Shyr Y., Olsen N.J., Aune T. Shared gene expression profiles in individuals with autoimmune disease and unaffected first-degree relatives of individuals with autoimmune disease. Human Molecular Genetics 2005, 14:1305-1314.
99. Sarkijarvi S., Kuusisto H., Paalavuo R., Levula M., Airla N., Lehtimaki T., et al. Gene expression profiles in Finnish twins with multiple sclerosis. BMC Medical Genetics 2006, 7:11.
100. Galligan C.L., Siebert J.C., Siminovitch K.A., Keystone E.C., Bykerk V., Perez O.D., et al. Multiparameter phospho-flow analysis of lymphocytes in early rheumatoid arthritis: implications for diagnosis and monitoring drug therapy. PloS ONE 2009, 4:e6703.
101. Pascual V., Chaussabel D., Banchereau J. A genomic approach to human autoimmune diseases. Annual Review of Immunology 2010, 28:535-571.
102. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nature Medicine 2002, 8:500-508.
103. Han M.H., Hwang S.I., Roy D.B., Lundgren D.H., Price J.V., Ousman S.S., et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008, 451:1076-1081.
104. Arthur A.T., Armati P.J., Bye C., Heard R.N., Stewart G.J., Pollard J.D., et al. Genes implicated in multiple sclerosis pathogenesis from consilience of genotyping and expression profiles in relapse and remission. BMC Medical Genetics 2008, 9:17.
105. Bennett L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. Journal of Experimental Medicine 2003, 197:711-723.
106. Alcorta D.A., Barnes D.A., Dooley M.A., Sullivan P., Jonas B., Liu Y., et al. Leukocyte gene expression signatures in antineutrophil cytoplasmic autoantibody and lupus glomerulonephritis. Kidney International 2007, 72:853-864.
107. Garcia-Romo G.S., Caielli S., Vega B., Connolly J., Allantaz F., Xu Z., et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Science Translational Medicine 2011, 3:73ra20.
108. Berthier C.C., Bethunaickan R., Gonzalez-Rivera T., Nair V., Ramanujam M., Zhang W., et al. Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis. Journal of Immunology 2012, 189:988-1001.
109. Srivastava R., Aslam M., Kalluri S.R., Schirmer L., Buck D., Tackenberg B., et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. New England Journal of Medicine 2012, 367:115-123.
110. Larman H.B., Zhao Z., Laserson U., Li M.Z., Ciccia A., Gakidis M.A., et al. Autoantigen discovery with a synthetic human peptidome. Nature Biotechnology 2011, 29:535-541.
111. Guedj J., Perelson A.S. Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology 2011, 53:1801-1808.
112. Ciupe S.M., Ribeiro R.M., Nelson P.W., Dusheiko G., Perelson A.S. The role of cells refractory to productive infection in acute hepatitis B viral dynamics. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:5050-5055.
113. Dahari H., Major M., Zhang X., Mihalik K., Rice C.M., Perelson A.S., et al. Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. Gastroenterology 2005, 128:1056-1066.
114. Pawelek K.A., Huynh G.T., Quinlivan M., Cullinane A., Rong L., Perelson A.S. Modeling within-host dynamics of influenza virus infection including immune responses. PLOS Computational Biology 2012, 8:e1002588.
115. Chaussabel D., Quinn C., Shen J., Patel P., Glaser C., Baldwin N., et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 2008, 29:150-164.